HMGB1 and polycystic ovary syndrome: In a recent study by Cirillo et al., they administered a treatment with 400 mg of ALA plus 1000 mg of MYO twice daily for three months, and once daily for further three months in PCOS adolescents and reported a significant reduction in insulin levels and in HMGB1 levels, which is a marker of inflammation, hypothesizing that ALA has a synergistic effect with MYO on lowering HMGB1 and improving insulin sensitivity.